Skip to main content

Barrett Elizabeth A.'s Form 4 filing

UroGen Pharma Ltd. (URGN) · filed Jan 7, 2022

Accession no.
0001209191-22-002305
Filed
Jan 7, 2022
Trade date
Jan 3-4, 2022
Filing delay
4 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $429.8K. It was filed 4 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Barrett Elizabeth A.CIK 0001764157Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2022Ordinary SharesMOption exerciseAcquired+105,689–F1–345,188Direct
Jan 4, 2022Ordinary SharesSSaleDisposed−46,968$9.15−$429,757.2298,220Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2022Ordinary SharesMOption exerciseDisposed−105,689$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)